Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q3 EPS of ($0.74), $0.01 better than the analyst estimate of ($0.75).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.